Posaconazole: A review of its use in the prophylaxis of invasive fungal infections

Drugs

Volumn 68, Issue 7, 2008, Pages 993-1016

  Frampton, James E ^a,b   Scott, Lesley J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Mycoses, treatment; Posaconazole, general

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; ERGOSTEROL; FLUCONAZOLE; HALOFANTRINE; ITRACONAZOLE; MIDAZOLAM; PHENYTOIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFABUTIN; TACROLIMUS; TERFENADINE; VINBLASTINE; VINCRISTINE; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS; ASPERGILLUS FUMIGATUS; CANDIDA; CELL DEATH; CELL MEMBRANE; CLINICAL TRIAL; COST UTILITY ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CROSS REACTIVITY; FUNGUS GROWTH; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION PREVENTION; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MEMBRANE BINDING; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; UNITED STATES; VOMITING; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; TRIAZOLES;

ASPERGILLUS; CANDIDA; ZYGOMYCETES;

EID: 43249107338     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868070-00008     Document Type: Review

References (122)

1. Keating GM. Posaconazole. Drugs 2005; 65 (11): 1553-67; discussion 1568-9
2. Bennett F, Saksena AK, Lovey RG, et al. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole. Bioorg Med Chem Lett 2006 Jan 1; 16 (1): 186-90
3. Xiao L, Madison V, Chau AS, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004 Feb; 48 (2): 568-74
4. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. CID 2008 Feb 1; 46: 327-60
5. Krishnan-Natesan S, Chandrasekar PH. Current and future therapeutic options in the management of invasive aspergillosis. Drugs 2008; 68 (3): 265-82
6. de Pauw B. Preventative use of antifungal drugs in patients treated for cancer. J Antimicrob Chemother 2004; 53: 130-2
7. Munayyer HK, Mann PA, Chau AS, et al. Posaconazole is a potent inhibitor of sterol 14-α-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004 Oct; 48 (10): 3690-6
8. Odds FC, Brown AJ, Gow AA. Antifungal agents: mechanisms of action. Trends Microbiol 2003 Jun; 11 (6): 272-9
9. Mann PA, Patel R, Chen G, et al. Posaconazole is a potent inhibitor of sterol 14 α-demethylation in zygomycetes [abstract no. M-1978 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
10. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006 Jun; 50 (6): 2009-15
11. Dodds AES, Alexander BD. Posaconazole. Drugs Today (Barc) 2005 Jun; 41 (6): 393-400
12. Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007 Apr; 20 (2): 188-96
13. Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther 2007; 29 (9): 1862-86
14. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007; 8 (8): 1167-78
15. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005 Dec; 5 (12): 775-85
16. Noxafil® (posaconazole) oral suspension. Product information Kenilworth (NJ): Schering Plough Corporation, 2006
17. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006 Mar; 50 (3): 917-21
18. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004 Mar; 48 (3): 201-5
19. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of posaconazole (Sch 56592) compared with those of intraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001 Oct; 45 (10): 2862-4
20. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 Aug; 41 (8): 3623-6
21. Manavathu EK, Abraham OC, Chandrasekar PH. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 2001 Mar; 7 (3): 130-7
22. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002 Apr; 46: 1032-7
23. Guinea J, Pelaez T, Alcala L, et al. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob Agents Chemother 2005 Aug; 49 (8): 3495-7
24. Manavathu EK, Cutright JL, Loebenberg D, et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000 Aug; 46: 229-34
25. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 Oct; 36 (10): 2950-6
26. Laverdiere M, Hoban D, Restieri C, et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002 Jul; 50 (1): 119-23
27. Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004 Jan; 53 (1): 74-80
28. Carrillo-Munoz A-J, Quindos G, Ruesga M, et al. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 2005; 55 (3): 317-9
29. Groll AH, Walsh TJ. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006; 49 Suppl. 1: 7-16
30. Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000 Aug; 44 (8): 2017-22
31. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001 Mar; 45 (3): 857-69
32. Hof H. A new, broad-spectrum azole antifungal: posaconazole - mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 49 Suppl. 1: 2-6
33. Hof H. Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur J Clin Microbiol Infect Dis. Epub 2008 Jan 19
34. Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob Agents Chemother 2003 Feb; 47 (2): 577-81
35. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, et al. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006 Sep; 44 Suppl.: 367-71
36. Trama JP, Mordechai E, Adelson ME. Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to intraconazole and posaconazole by real-time PCR and pyrosequencing. J Clin Microbiol 2005 Feb; 43 (2) 906-8
37. Chau AS, Gurnani M, Hawkinson R, et al. Inactivation of sterol 5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother 2005 Sep; 49 (9): 3646-51
38. Chau AS, Mendrick CA, Sabatelli FJ, et al. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2124-31
39. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002 Feb; 46 (2): 556-7
40. Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant aspergillosis [letter]. New Engl J Med 2007 Apr 5; 356 (14): 1481-3
41. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of CYP51A alterations. Antimicrob Agents Chemother 2007 Jun; 51 (6): 1897-904
42. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J Clin Microbiol 2004 Jul; 42 (7): 3142-6
43. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 Jan 25; 356 (4): 335-47
44. Center for Drug Evaluation and Research. Microbiology review: posaconazole [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2006/ 022003s000_Noxafil_MicroR.pdf [Accessed 2008 Feb 8]
45. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 Jan 25; 356 (4): 348-59
46. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006 Feb; 50 (2): 658-66
47. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006 May; 50 (5): 1881-3
48. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007 Feb; 51 (2): 495-502
49. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy subjects. Br J Clin Pharmacol 2004 Feb; 57 (2): 218-22
50. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007 Jun; 27 (6): 825-34
51. Krishna G, Martinho M, Chandrasekar P, et al. Pharmaco-kinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharnamacotherapy 2007 Dec; 27 (12): 1627-36
52. Courtney R, Martinho M, Lim J, et al. Evaluation of the effect of age, weight, race, and gender on the plasma concentrations of posaconazole in HIV-infected patients with oropharyngeal or esophageal candidiasis [abstract no. P1217]. Clin Microbiol Infect 2003 May; 9 Suppl. 1: 289
53. Maertens J, Langston A, Ullmann A, et al. Posaconazole prophylaxis in haematopoietic stem cell transplant recipients and neutropenic patients: pharmacokientics and safety analysis [abstract no. P707]. Bone Marrow Transplant 2007 Apr; 39 Suppl. 1: S165
54. Courtney RD, Laughlin M, Gontz H, et al. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease [abstract no. 1852]. Annual Meeting and Exposition of the American Association of Pharmaceutical Sciences; 2000 Oct 29-Nov 2; Indianapolis (IN)
55. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005 Feb; 45 (2): 185-92
56. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007 Mar; 23 (3): 545-52
57. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004 Mar; 48 (3): 804-8
58. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 Sep; 47 (9): 2788-95
59. Courtney R, Wexler D, Statkevich P, et al. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers [abstract no. A-1838]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA)
60. Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and phenytoin [abstract no. A-28]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago (IL)
61. Courtney R, Sansone A, Statkevich P, et al. Assessment of the pharmacokinetic (PK), pharmacodynamic (PD) interaction potential between posaconazole and glipizide in health volunteers [abstract no. PII-63]. Clin Pharmacol Ther 2003 Feb; 73 (2): P45. Plus poster presented at the 2003 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2003 Apr 2-P45. Plus poster presented at the 2003 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2003 Apr 2-5; Washington, DC
62. Ezzet F, Wexler D, Courtney R, et al. Comparative bioavailability of oral posaconazole (POS) in different dosage regimens: a population pharmacokinetic analysis [abstract no. A-1565]. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy Abstracts; 2003 Sep 14-17; Chicago (IL)
63. Krishna G, Moton A, Ma L, et al. Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole [abstract no. 1264]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona
64. Cornely OA, Maertens J, Winston D, et al. Pharmacokinetics of oral posaconazole in neutropenic patients with acute myelogenous leukemia [abstract no. A-1096; plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 17-20; San Francisco (CA)
65. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 Sep; 48 (9): 3543-51
66. Noxafil® 40mg/ml oral suspension. Summary of product characteristics. Brussels: Schering-Plough Ltd., 2006 Oct 30
67. Moton A, Ma L, Krishna G, et al. The safety, tolerability, and pharmacokinetics of the antifungal posaconazole in hepatic impairment [abstract no. 1265]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona
68. Wexler D, Courtney R, Richards W, et al. Effect of posacona zole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 Apr; 21 (5): 645-53
69. Moton A, Ma L, Krishna G, et al. Effect of oral posaconazole (POS) on the pharmacokinetics (PK) of sirolimus [abstract no. A-775]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
70. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and metaanalysis. J Clin Oncol 2007 Dec 1; 25 (34): 5471-89
71. Greiner R-A, Russ W, Imhof A. Cost effectiveness of posaconazole versus standard azole therapy for the prevention of invasive fungal infections in high-risk patients in Switzerland [abstract]. 34th Annual European Group for Blood and Marrow Transplantation meeting; 2008 30 Mar-2 Apr; Florence
72. O'Sullivan AK, Weinstein MC, Pandya A, et al. Cost-effectiveness of posaconazole vs fluconazole in the prevention of invasive fungal infections among patients with graft-versus-host disease in the US [abstract no. 3336]. Blood 2007 Nov 16; 110 (11 Pt 1): 979A
73. Grau S, de la Camara E, Carreras MA, et al. Cost-effectiveness of posaconazole vs. fluconazole in the prevention of invasive fungal infections among patients with graft-versus-host disease in Spain [abstract no. 1028]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona
74. O'Sullivan AK, Pandya A, Thompson D, et al. Cost-effectiveness of posaconazole versus standard azole therapy in the prevention of invasive fungal infections among high-risk neutropenic patients in the U.S [abstract no. 3311]. Blood 2006 Nov; 108: 944-5. Plus poster presented at the American Society of Hematology 48th Annual Meeting and Exposition; 2006 Dec 9-12; Orlando (FL)
75. Grau S, de la Camara R, Sanz M, et al. Cost-effectiveness of posaconazole versus standard azole treatment (fluconazole or itraconazole) in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain [abstract no. 1027]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona
76. Stam WB, O'Sullivan Ak, Rijnders B, et al. Economic evaluation of posaconazole versus standard azole prophylaxis in high risk neutropenic patients in the Netherlands [abstract no. 3335]. Blood 2007 Nov 16; 110 (11 Pt 1): 979A
77. Tahami Monfared AA, O' Sullivan A, Papadopoulos G, et al. Posaconazole versus standard azole therapy in the prophylaxis against invasive fungal infections among high-risk neutropenic patients in Canada: a cost-effectiveness analysis [abstract no. 1029]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona
78. Thalheimer M, Cornely OA, Hoppe-Tichy T, et al. Pharmaco-economic analysis of posaconazole versus standard azole prophylaxis in high-risk neutropenic AML/MDS patients in Germany [abstract no. 1031]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona
79. Collins CD, Kaul DR. Cost effectiveness analysis evaluating posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [abstract no. O-1870] 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 2007 Sep 17-20; Chicago (IL)
80. Sansone A, Courtney R, Mellars L, et al. Posaconazole has no clinically significant effect on the QTc interval in healthy volunteers [abstract no. A-1100 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
81. Schering-Plough Canada Inc. Spriafil® (posaconazole) is approved by Health Canada for prevention and treatment of invasive fungal infections [media release]. Kirkland (QC), 2007
82. Kontoyiannis DP. A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America. Pharmacotherapy 2001 Aug; 21 (8 Pt 2): 175-187S
83. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005 Sep 17; 366 (9490): 1013-25
84. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004 Feb; 24 (2 Pt 2): 4S-28S; quiz 29S-32S
85. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006; 3 (1): 35-40
86. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001 Sep 1; 33 (5): 641-7
87. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immuno-compromised patients. Drugs 2007; 67 (11): 1567-601
88. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006 Sep; 20 (3): 485-506
89. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care 2001 Mar; 10 (1): 56-62
90. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55: 809-18
91. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007 Apr; 78 (4): 275-82
92. Maertens J, Frere P, Lass-Florl C, et al. European guidelines for primary antifungal prophylaxis in leukaemia patients. 14th International Symposium of Infections in the Immuno-compromised Host; 2006 July 2-5; Crans-Montana, Switzerland
93. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67 (13): 1803-12
94. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 2004 Dec; 18 (14 Suppl. 13): 9-14
95. Bierman B, Bubalo J. Invasive fungal infections in immuno-compromised patients: a review of antifungal agents. US Pharm 2006; 1: 3-15
96. Mantadakis E, Samonis G. Novel preventative strategies against invasive aspergillosis. Med Mycol 2006 Sep; 44 Suppl.: 327-32
97. Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006 Dec; 19 (6): 571-6
98. Stevens DA. Diagnosis of fungal infections: current status. Journal of Antimicrobial Therapy 2002; 49: 11-9
99. van't Wout JW, van Dissel JT. Fungal infection in hematooncologic patients: better to prevent than treat? Blood 2004 Feb 15; 103 (4): 1182-3
100. Leather HL, Wingard JR. Prophylaxis, empirical therapy or fungal infections in immunocompromised patients: which is better for whom? Curr Opin Infect Dis 2002 Aug; 15 (4): 369-75
101. Gonzalez AV, Ullmann AJ, Almyroudis NG, et al. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J Natl Compr Canc Netw 2008 Feb; 6 (2): 175-82
102. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000 Sep 15; 96 (6): 2055-61
103. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients - recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Transplantation. MMWR Morb Mortal Wkly Rep 2000; 49 (RR-10): 1-128
104. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51
105. Weiler S, Bellmann R. Posaconazole prophylaxis in hematologic cancer [letter]. N Engl J Med 2007 May 24; 356 (21): 2214
106. Nagappan V, Deresinki S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007 Dec 15; 45 (12): 1610-7
107. Ferrara JLM. Graft-versus-host disease. New Engl J Med 1991; 324: 667-74
108. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005; 6: 93-102
109. van Nieuwkoop C, van Dissel JT. Posaconazole prophylaxis in hematologic cancer [letter]. N Engl J Med 2007 May 24; 356 (21): 2215-8
110. Mycamine® (micafungin sodium) for injection. Prescribing information. Deerfield (IL): Astellas Pharma Inc., 2007 Aug
111. VFEND® I.V. (voriconazole) for injection VFEND® tablets (voriconazole) for oral suspension. Prescribing information. New York (NY): Pfizer Roerig, 2006 Nov
112. VFEND® 50 mg and 200 mg film-coated tablets, VFEND® 200 mg powder for solution for infusion, VFEND® 40 mg/mL powder for oral suspension. Summary of product characteristics. Sandwich: Pfizer Limited, 2007 Aug 2
113. CANCIDAS® (caspofungin acetate) for injection. Prescribing information. Whitehouse Station (NJ): Merck & Co. Inc., 2005 Feb
114. CANCIDAS® (formerly Caspofungin MSD). Summary of product characteristics. Hoddesdon: Merck Sharp and Dohme Limited, 2007 Feb 1
115. Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogenic blood and marrow transplant (BMT) patients [abstract no. 163]. Blood 2007; 11: 110
116. Kauffman CA. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006 Oct; 9 (5): 483-8
117. Kauffman CA, Malani AN, Easley C, et al. Posaconazole. Nat Rev Drug Discov 2007 Mar; 6 (3): 183-4
118. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67 (2): 269-98
119. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006 Jun; 27 Suppl. 1: 12-6
120. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections V.1.2008 [online]. Available from URL: http://www.nccn.org [Accessed 2008 Mar 20]
121. Maertens J, Frere P, Lass-Florl C, et al. 2007 update of the ECIL-1 guidelines for antifungal prophylaxis in leukaemia patients, including allogeneic HSCT recipients [online]. Available from URL: http://www.ichs.org/ Ecilslides/ECIL2%20%20Antifungal%20prophylaxis%20update%202007.pdf [Accessed 2008 Mar 25]
122. Schwarzinger M, Baillot S, Beauchamp C, et al. Cost-effectiveness of antifungal strategies in high-risk neutropenic patients [abstract no. 4340]. Blood 2007 Nov 16; 110 (11 Pt 2): 153